Mahesh V. Madhavan,Emad Hakemi,Rishi Neeranjun,Hussein Rahim,Shayan Nabavi Nouri,Erin Flattery,Megha Prasad,Michael Collins,Dimitri Karmpaliotis,Ziad A. Ali,Sahil A. Parikh,Torsten Vahl,Amisha Patel,Tamim Nazif,Khady Fall,Akiko Maehara,Martin B. Leon,Ajay J. Kirtane,Jeffrey W. Moses
While not available for clinical use in the United States, dedicated drug-coated balloons (DCB) are currently under investigation for the management of coronary in-stent restenosis (ISR). Peripheral drug-coated balloons (P-DCB) have been used off-label for coronary ISR. Further data regarding this practice are needed. We aimed to describe outcomes in patients who underwent off-label P-DCB angioplasty for coronary ISR.